HOUSE-WELLNESS-FOODS
30.3.2021 12:32:10 CEST | Business Wire | Press release
Vietnam is a nation that has seen its share of turmoil and suffering over the past century, and emerged from it with strength, enthusiasm, dedicated to progress and self-sufficiency. Over the past 50 years its participation on the global stage has steadily risen, with ever-increased attention to commerce, health, and education.
As much as 35% of Vietnam’s aquacultural activity is built around river farming of the juvenile striped catfish [Pangasianodon hypophthalmus ] , making it the world’s largest producer of this nutritious staple, not only for its own consumption but for export to China, Europe, and elsewhere.
Vietnam’s story is one of many that expose the dual edge of farming to emerging populations. It’s been the keystone of civilization’s advancement since the dawn of humankind, but where resources are limited and need is great, farming’s potential hazards become viciously clear. Overstocked waters turn hazardous to human life due to excessive waste production and a rise in bacteria, parasites, fungi, and viruses. Overstocked waters produce fish that are increasingly malnourished, enervated, injured, and unable to reproduce.
The reflex response to this blight has been the use of antibiotics to keep weakened fish populations alive. Apart from expense, before long, disease-inducing agents mutate to resist the antibiotic, which, in turn, leads to the use of more varied antibiotics, causing a dangerous downward spiral . All the while antibiotics are entering the food chain and turning up in the human metabolic system to unpredictable, deleterious effect. Promise quickly turns to peril for the farmer, for the consumer, and for the future of vital aquaculture.
Feed LP20® can reverse this tide…
The details of this new study show its dramatic impact. In summary, researchers fed test stocks a diet supplemented with heat-killed Lactobacillus plantarum , strain L-137, the active ingredient in Feed LP20® . Key to the high effectiveness of Feed LP20® is the heat-killing process. It fully utilizes the strain’s characteristics, an area where House Wellness Foods holds an unparalleled position of authority based upon years of peer-reviewed testing and research, and continuous refinement of the development process. Heat treatment hardens bacillary cell walls and fixes their genetic material. Not only does this enable HK-L137 to resist initial breakdown in the upper gastric system, but it can be cooked, processed, stored, and administered in an aquatic environment without compromising potency. Further, both its ability to stimulate immune cytokine interleukin 12 and its shelf life far surpass that of any living lactobacillus supplement.
House Wellness Foods and the introduction of immunobiotics
Immunobiotics promote health by triggering immune responses in the mucosa. House Wellness Foods , one of Japan’s most trusted names in food production, began its exploration of immunobiotics and their ability to bolster human immune response, support liver function, and ameliorate the causes of chronic disease over three decades ago, and the culmination of their intensive research and meticulous development was their flagship Immuno-LP20® , with its active component of 20% heat-treated Lactobacillus plantarum L-137 (HK-L137). This potent lactobacillus follows a dual course on assimilation. It initiates production of signal molecule IL-12 and IFN-β cells — the latter being the most important single cytokine responsible for inhibiting viral multiplication; and it subsequently stimulates T cell activity and the production of both NK and cytotoxic T (CTL) effector cells, boosting innate immunity and fostering antibody creation as an adjunct to the adaptive immune response.
House followed the worldwide success of Immuno-LP20® , with the development of Feed LP20® , an alternative to antibiotics, and to the costly, unreliable, and lengthy process of cultivating disease-resistant strains of livestock. The overarching principle of immunobiotic therapy in both land-based and aquatic livestock is that the power to fight disease already exists within every living cell of the organism. Prior to the present study, Feed LP20® proved its remarkable effectiveness in other aquatic stock, including white leg shrimp and Nile tilapia . It recently began marketing in the EU as a complementary feed for poultry, swine, and salmonid.
The proof is in the food chain
The study shows that juvenile striped catfish fed HK-L137-supplemented diets exhibited higher final weight and specific growth rate than controlled stock given ordinary feed. The fish showed higher survival rate, longer life, better feed conversion ratios, weight gain, better protein efficiency ratios, and increased reproductive capacity. Further, a test sub-group was administered a bacterial challenge mirroring a real-life scenario in Vietnamese river farms of their most devastating bacterial threat, Bacillary Necrosis Disease (BNP), caused by the bacterial agent Edwardsiella ictaluri . Part of the test group was injected with this agent, and in every case the cumulative mortality of HK L-137-supplemented groups was lower than the group fed control diet.
Fitter fish, more successful farming, greater financial stability — all of this originating from the power of Feed LP20® , comprising 20% HK-L137 , to sustain health through enhanced immunity at the very cellular level. The new study shows the promise of House Wellness Foods’ Breakthrough Feed LP20®, and points to the future of a shared world that is often fragile, yet always filled with hope.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
